Glenmark Pharmaceuticals has informed about press release titled ‘Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting’.
The above information is a part of company’s filings submitted to BSE.